Caplin Point Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 22, 2025
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caplin Point Laboratories has filed its Annual Report for FY25 (year ended March 31, 2025) and the notice for its 34th AGM, scheduled for September 22, 2025 via video conferencing. The company reported its highest-ever total revenue of ₹2,034 crore, up 15.5% YoY, with operating revenue at ₹1,938 crore. Profit after tax grew 17.3% to ₹541 crore, EBITDA rose 20.2% to ₹743 crore, and cash reserves stood at ₹1,180 crore (up 29%), keeping the company debt-free. Gross margins reached 60.2% and R&D spend hit a record ₹89 crore (4.6% of revenue). The board declared total dividends of ₹45.6 crore (300% of equity capital). The US front-end subsidiary Caplin Steriles USA Inc. generated USD 3.2 million in its first eight months, launching 24 products, while CSL facility cleared US-FDA inspection with zero observations.
Routine regulatory filing with no immediate price action expected, but the strong FY25 results — record revenue, ~17% PAT growth, debt-free balance sheet with ₹1,180 crore cash, and visible US business traction — reinforce the company's growth narrative ahead of the AGM. Shareholders may note the 300% dividend declaration and ongoing ₹1,000+ crore capex programme funded entirely from internal accruals.